PMID- 24675266
OWN - NLM
STAT- MEDLINE
DCOM- 20150618
LR  - 20140328
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 18
IP  - 2
DP  - 2014 Apr
TI  - Adverse event management strategies: optimizing treatment with regorafenib in 
      patients with metastatic colorectal cancer.
PG  - E19-25
LID - 10.1188/14.CJON.E19-E25 [doi]
AB  - Patients with metastatic colorectal cancer (mCRC) frequently experience 
      treatment-related adverse events (AEs), which may lead to nonadherence or 
      discontinuation from their treatment regimen. In the phase 3 CORRECT study, the 
      addition of regorafenib to best supportive care (BSC) significantly increased 
      overall survival and progression-free survival compared with placebo plus BSC in 
      patients with mCRC who had progressed on all approved standard care therapies. 
      Although regorafenib showed an acceptable safety profile, patients experienced 
      treatment-related AEs such as hand-foot skin reaction, hypertension, oral 
      mucositis, diarrhea, fatigue, and liver abnormalities. The goal of this article 
      is to help oncology nurses implement a strategic, proactive approach to AE 
      management in patients mCRC treated with regorafenib. The article reviews the 
      most common AEs associated with regorafenib in patients who participated in the 
      CORRECT study and provides a strategy and practical measures that nurses can 
      apply to AE management. In addition, the article provides direction and guidance 
      for educating patients and their caregivers on recognizing and managing potential 
      side effects of regorafenib.
FAU - Mitchell, Jessica
AU  - Mitchell J
AD  - Mayo Clinic, Rochester, MN.
FAU - Khoukaz, Taline
AU  - Khoukaz T
AD  - University of Southern California Norris Comprehensive Cancer Center in Los 
      Angeles.
FAU - McNeal, Deborah
AU  - McNeal D
AD  - Charleston Hematology Oncology Associates in South Carolina.
FAU - Brent, Lori
AU  - Brent L
AD  - Jackson Oncology Associates in Mississippi.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Diarrhea/chemically induced
MH  - Fatigue/chemically induced
MH  - Humans
MH  - Hypertension/chemically induced/drug therapy
MH  - Liver/drug effects/physiopathology
MH  - Neoplasm Metastasis
MH  - Phenylurea Compounds/*adverse effects/therapeutic use
MH  - Pyridines/*adverse effects/therapeutic use
MH  - Stomatitis/chemically induced
OTO - NOTNLM
OT  - biotherapy/targeted therapy
OT  - gastrointestinal malignancies
EDAT- 2014/03/29 06:00
MHDA- 2015/06/19 06:00
CRDT- 2014/03/29 06:00
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/06/19 06:00 [medline]
AID - W77432258820P54J [pii]
AID - 10.1188/14.CJON.E19-E25 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2014 Apr;18(2):E19-25. doi: 10.1188/14.CJON.E19-E25.